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Abstract
Rationale: Key biologic effects of the alpha-particle emitter Actinium-225 in comparison to the beta-particle emitter
Lutetium-177 labeled somatostatin-analogue DOTATOC in vitro and in vivo were studied to evaluate the significance of
cH2AX-foci formation.
Methods: To determine the relative biological effectiveness (RBE) between the two isotopes (as - biological consequence of
different ionisation-densities along a particle-track), somatostatin expressing AR42J cells were incubated with Ac-225-
DOTATOC and Lu-177-DOTATOC up to 48 h and viability was analyzed using the MTT assay. DNA double strand breaks
(DSB) were quantified by immunofluorescence staining of cH2AX-foci. Cell cycle was analyzed by flow cytometry. In vivo
uptake of both radiolabeled somatostatin-analogues into subcutaneously growing AR42J tumors and the number of cells
displaying cH2AX-foci were measured. Therapeutic efficacy was assayed by monitoring tumor growth after treatment with
activities estimated from in vitro cytotoxicity.
Results: Ac-225-DOTATOC resulted in ED50 values of 14 kBq/ml after 48 h, whereas Lu-177-DOTATOC displayed ED50 values
of 10 MBq/ml. The number of DSB grew with increasing concentration of Ac-225-DOTATOC and similarly with Lu-177-
DOTATOC when applying a factor of 700-fold higher activity compared to Ac-225. Already 24 h after incubation with 2.5–
10 kBq/ml, Ac-225-DOTATOC cell-cycle studies showed up to a 60% increase in the percentage of tumor cells in G2/M
phase. After 72 h an apoptotic subG1 peak was also detectable. Tumor uptake for both radio peptides at 48 h was identical
(7.5%ID/g), though the overall number of cells with cH2AX-foci was higher in tumors treated with 48 kBq Ac-225-DOTATOC
compared to tumors treated with 30 MBq Lu-177-DOTATOC (35% vs. 21%). Tumors with a volume of 0.34 ml reached
delayed exponential tumor growth after 25 days (44 kBq Ac-225-DOTATOC) and after 21 days (34 MBq Lu-177-DOTATOC).
Conclusion: cH2AX-foci formation, triggered by beta- and alpha-irradiation, is an early key parameter in predicting response
to internal radiotherapy.
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Introduction
The clinical impact of tumor-targeted radionuclide therapy,
primarily using beta-particle emitters, is growing and treatment
methods for metastasized malignancies with unfavorable prognosis
have been developed. In patients with metastasized neuroendo-
crine tumors, high somatostatin receptor status provides the
opportunity for peptide receptor radionuclide therapy (PRRT)
with commonly used somatostatin analogues, e. g., octreotide,
DOTATOC and DOTATATE, radiolabelled with the beta-
emitting nuclide Lutetium-177 (177Lu, half-life 6.73 d, 0.498 MeV)
leading to tumor regression and symptom reduction [1]. Never-
theless, kidney and hematologic toxicities after PRRT have been
reported [2]. Progressive disease and early relapses in patients with
radio-resistant tumors were also described.
To further improve the PRRT strategy for neuroendocrine
tumors, labeling of somatostatin analogues with an alpha-particle
emitter could be an attractive option. Alpha-particle emitters are
PLOS ONE | www.plosone.org 1 February 2014 | Volume 9 | Issue 2 | e88239
characterized by a high energy and high linear energy transfer
(LET) causing high cellular cytotoxicity at the site of radionuclide
decay [3]. Compared to beta-particles and gamma irradiation the
higher LET of alpha-particles leads to denser ionisation events
along the particle track. This, in turn leads to a higher fraction of
double strand breaks per track length and therefore a higher
biological effectiveness. Thus, the same energy transferred to tissue
is more toxic for alpha particles than for beta particles and a
respective factor, the relative biological effectiveness (RBE) has to
be taken into account to enable comparability between doses from
different radiation types. This RBE is known to be in the range of
5–10 for alpha-particles over beta-particles. Furthermore, the
short range of alpha-particles (,100 microns) is promising for
treatment of tumor micrometastases and reduction of side effects
in healthy tissue. Indeed, efficacy of tumor-specific antibodies and
peptides labelled with alpha-particle emitting nuclides, e. g.,
Actinium-225 (225Ac) and Bismuth-213 (213Bi) were described
in vitro and in vivo [4,5].
225Ac (half-life 9.9 d, 5.935 MeV) has six daughters in its decay
chain – generating in total four alpha-particles – finally resulting in
stable Bismuth-209 at the end [6]. After 221Fr and 217At, 213Bi
(half-life 46 min) is one daughter of 225Ac that decays mainly
(98%) by beta-emission, producing an alpha-emitter 213Po (half-life
4.2 ms, 8.375 MeV), but also has a direct alpha-emission (2%,
5.87 MeV) to 209Tl (half-life 2.2 min, 3.98 MeV). Because of the
longer half-life and numerous alpha-particle emissions, radiother-
apy with 225Ac has been reported to be much more cytotoxic
compared to the very short lived alpha emitter 213Bi (half live
46 min) [7]. For example, the tumor-homing peptide, F3, labelled
with the alpha emitters 213Bi- and 225Ac significantly prolonged
survival of mice with peritoneal carcinomatosis along with the
absence of severe toxic side effects [8]. Also, therapeutic efficacy
and nephrotoxicity of 225Ac-DOTATOC has been studied in a
preclinical mouse model of neuroendocrine tumors where a
therapeutic window between tumor efficacy and long-term toxicity
was demonstrated [9].
Despite promising results of alpha-targeted therapy, few data
are available about the biological and molecular mechanisms of
tumor cell damage. In particular, a number of distinct cellular
effects occur between an ionization event and final cell death.
Within these pathways, for example, cellular properties like
radiation sensitivity or resistance are determined. Apart from
radiation properties like LET and range in tissue, dose rates may
also have a major impact on biologic responses. Therefore, dose-
rate effects should be considered when comparing radioisotopes
that vary significantly in terms of their physical half-life.
Furthermore, variations in the physical properties of radiation
may provoke different cellular responses depending on the
relevant pathways, e.g., cell death and DNA repair mechanisms.
In multiple resistant leukemia and non-Hodgkin Lymphoma cells,
re-activation of apoptotic pathways were reported to be key
mechanisms of alpha radiation for overcoming treatment
resistance [10,11].
The comparison of alpha- and beta-particle emitters with
similar half-lives at equitoxic doses could provide new insights into
the cellular response after high and low-LET radiation. The aim of
the study is to compare the alpha-particle emitter 225Ac- and beta
emitter 177Lu-labelled somatostatin analogue DOTATOC in
terms of DNA damage induction and the level of cell death. We
studied this in the neuroendocrine cell line AR42J, which is
characterized by expression of wild-type p53 and strong somato-
statin expression of target epitopes, where intact apoptotic
pathways have been demonstrated [12]. We determined the level
of cH2AX as a reliable and sensitive indicator of DNA double-
strand breaks (DSB) and apoptosis, which is the main mechanism
of cell death following treatment with the radioisotopes.
Materials and Methods
Material
The antibodies against Hsp90, p21 and p53 were bought from
Santa Cruz Biotechnology (Heidelberg, Germany). The antibody
against ATM was obtained from Cell Signaling (Boston, MA,
USA) and the antibody against phosphorylated ATM was from
Merck Millipore (Darmstadt, Germany). PARP-1 antibody was a
kind gift of Prof. Dr. Alexander Bu¨rkle (University of Konstanz,
Germany).
Chemistry
Radiolabeling of somatostatin analogues. All chemicals
and the peptide DOTATOC were obtained from commercial
sources.
225Ac was produced at the European Commission Joint
Research Centre, Institute for Transuranium Elements, Karls-
ruhe, Germany [13]. 225Ac was quantified with a gamma counter
using the gamma emissions of its daughter nuclides 221Fr (half-life:
4.9 min) and 213Bi (half-life: 46.6 min) using a 190–247 keV and
399–488 keV energy window, respectively, after radiochemical
equilibrium was reached. The synthesis starting from 10 ml of
DOTATOC (jpt peptides, Germany) (0.5 mg/ml) and 1–2 MBq
225Ac (0.1 M HCl) in 0.1 M Tris buffer pH 9.0 yielded 225Ac-
DOTATOC within 30 min at 90uC and a radiochemical purity of
typically .95% assessed via ITLC. The specific activity of 225Ac-
DOTATOC was calculated to 0.2–0.4 MBq/mg.
177Lu was kindly provided by IDB Holland, Baarle-Nassau, The
Netherlands, and counted in a calibrated dose activimeter or in a
gamma counter using an energy window of 126–159 keV. For
radiolabeling of DOTATOC, 200 ml of 177LuCl3 solution (4 GBq;
IDB Holland, Baarle-Nassau, The Netherlands) was incubated
with 100 mg DOTATOC in 400 ml 0.4 M sodium acetate buffer
with gentisic acid (2,5-dihydroxy benzoic acid, 25 mg/ml) at 95uC
for 30 min. Radiochemical purity was .99% and specific activity
,40 MBq/mg.
Cellular Studies
Cell culture. The p53 wild-type tumor cell line AR42J, a rat
pancreatic acinar carcinoma cell line, was obtained from ATCC-
LGC Standards, Wesel, Germany and cultured in DMEM (high
glucose, 4.5 g/l; PAA, Pasching, Austria) supplemented with 10%
fetal bovine serum (FBS) and 1% penicillin-streptomycin. The cells
were cultured at 37uC, 5% CO2 and 95% humidity in a CO2
incubator (Heracell, Heraeus, Hanau, Germany; Binder, Ger-
many).
SDS-PAGE and western blot analysis. Following irradia-
tion with 5 Gy, cells were harvested in 1x La¨mmli loading buffer.
Samples were then subjected to SDS-PAGE followed by transfer
onto a nitrocellulose membrane (Whatman, Dassel, Germany)
using a wet-blot chamber (GE Healthcare, Mu¨nchen, Germany).
The membrane was blocked with 5% (w/v) non-fat dry milk in
PBS containing Tween-20 [0.1% (v/v), PBS-T] for 1 h at room
temperature (RT). Subsequently, the membrane was incubated
with the respective primary antibody diluted in PBS-T for 1 h at
RT. After washing the membrane, it was incubated with the
appropriate secondary antibody coupled to horseradish peroxidase
(Santa Cruz Biotechnology, Heidelberg, Germany) for 1 h. After
further washing steps, bound antibodies were visualized by
chemiluminescence detection using Western LightningH Plus-
ECL (Perkin Elmer, Rodgau, Germany).
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Cell viability. Cell viability was analyzed for up to 48 h after
treatment of 225Ac-DOTATOC or 177Lu-DOTATOC, respec-
tively. 26104 cells were seeded into a 96 well cell culture plate and
incubated for 24 h. Next, respective compound was added in
increasing concentrations (0.001 to 250 kBq/ml 225Ac-DOTA-
TOC and 5 to 40,000 kBq/ml 177Lu-DOTATOC) to the cells for
24 h and 48 h. Incubation of tetrazolium salt MTT was
performed at a final concentration of 50 mg/ml at 37uC in the
dark for 60 min. After that, supernatant was completely removed,
cells were lyzed with 100 ml DMSO and absorption was detected
at 550 nm and 690 nm as a reference wavelength.
Alkaline comet assay. Formation of DNA damage after
exposure to 225Ac-DOTATOC and 177Lu-DOTATOC, respec-
tively, was assayed by single-cell gel electrophoresis after alkaline
cell lysis as described previously [14,15]. Agarose embedded cells
on a slide were first incubated in lysis buffer (2.5 M NaCl,
100 mM EDTA, 10 mM Tris, 1% sodium lauroylsarcosinate,
pH 10) for 1 h at 4uC. After a second incubation period in
300 mM NaOH and 1 mM EDTA (pH.13) for 15 minutes at
4uC, electrophoresis (25 V/300 mA) was carried out for 15
minutes at 4uC. Cells were fixed in 100% ethanol and stained
with propidium iodide (PI). The DNA comets were visualized with
a fluorescence microscope and quantified by determination of the
tail moment (percentage of DNA in the tail multiplied by the
length between the center of the head and tail) [16] using Komet
4.0.2 software (Kinetic Imaging Ltd., Merseyside, UK). Per
treatment 50 nuclei in total were measured (mean 6 standard
deviation from at least three independent experiments).
cH2AX phosphorylation in vitro. Cells were seeded onto
cover slides. After treatment with 225Ac-DOTATOC or 177Lu-
DOTATOC, cells were fixed with 4% paraformaldehyde for
15 min at room temperature, following incubation with ice-cold
methanol (220uC, 10 min). After blocking with PBS containing
0.3% Triton-X-100 and 5% BSA (w/v) (1 h, room temperature)
incubation with Anti-phospho-Histone H2A.X(Ser139) mouse
monoclonal antibody (1:750, Millipore) was conducted overnight
at 4uC. Incubation with the secondary fluorophore-labelled
antibody (AlexaFluor 488 goat anti-mouse, 1:1000, Invitrogen)
was performed for 1 h at room temperature in the dark. For
immunofluorescence microscopy of cH2AX a Zeiss Imager.M1
(Carl Zeiss AG, Oberkochen, Germany) was used. Values are
given as mean 6 standard deviation from at least three
independent experiments with 50 nuclei each being analyzed.
Cell cycle measurements. Cell cycle distribution of the cells
was determined by flow cytometry DNA analysis. After treatment
of 2.56105 cells for 24, 48, 72 and 96 h with 225Ac-DOTATOC
or 177Lu-DOTATOC, respectively, cells were washed with PBS
and detached from the cell culture flask by addition of trypsin.
After centrifugation for 5 min at 1500 rpm at 4uC, cells were
washed once with ice-cold PBS and fixed in 70% ethanol at 20uC
for at least 60 min. Ethanol-fixed cells were washed again, treated
with 1 mg/ml ribonuclease I (Sigma-Aldrich) for 60 min and
stained with 10 mg/ml propidium iodide (Sigma-Aldrich) in the
dark. Flow cytometry analysis was performed on a FACSCali-
burTM Flow Cytometer (Becton Dickinson, Heidelberg, Germany)
by use of the CellQuest Pro software. For cell cycle analysis,
10,000 events were collected in the single-events region with a
total event rate not exceeding 300 events/second.
Apoptosis quantification. Trypsinized adherent cells were
resuspended in cold PBS and then fixed in ice-cold 70% ethanol
for a minimum of 60 min. After RNase (1 mg/ml) digestion for one
hour DNA was stained with propidium iodide (PI; 10 mg/ml) in
PBS. For each sample 10,000 cells were subjected to flow
cytometric analysis using a FACSCaliburTM Flow Cytometer
(Becton Dickinson, Heidelberg, Germany). The number of
apoptotic cells (subG1 fraction) was calculated using the software
WinMDI 2.9.
In vivo Experiments
Treatment of AR42J-xenograft tumors in nude mice. All
animal procedures and experiments were carried out according to
the guidelines of the German Regulations for Animal Welfare.
The protocols were approved by the local Ethical Committee for
Animal Experiments (Landesuntersuchungsamt Rheinland-Pfalz,
23 177-07/G10-1-013).
BALB/c nu/nu mice (Charles River) with an age of 9–10 weeks
and an average weight of 20 g were injected subcutaneously with
5?106 AR42J cells into the right flank and randomly divided into
groups of 2–3 animals. After the xenograft tumor reached 0.5 cm
(14 days post injection) in diameter either 47 kBq of 225Ac-
DOTATOC or 30 MBq of 177Lu-DOTATOC were intravenous-
ly injected into the tail vain. The reference groups analogously
received 0.9% sodium chloride solution, or respectively, 1 mg of
unlabelled DOTATOC (n= 3). 48 h after treatment, all mice were
sacrificed and tumor and major organs (kidney, liver, lung, heart,
muscle) were dissected. The weight and activity were measured for
each tissue section. Tumor samples were fixed in 4% formalin and
paraffin embedded for histological analyses.
In a second experiment, mice carrying AR42J tumors of
approximately 0.3 cm3 were treated intravenously with either
44 kBq (63.5, n = 3) 225Ac-DOTATOC or with 34 MBq (64.1,
n = 4) 177Lu-DOTATOC with a single injection and compared to
growth control (n = 4). After treatment tumors were measured in
two dimensions trice weekly with calipers until exponential growth
phase was clearly reached and mice were then sacrificed. For each
time point, the mean tumor sizes from all animals in one group
were calculated and plotted over time. Statistical analyses were
performed using SPSS, version 20 (SPSS Inc., Chicago, IL, USA)
with a linear model for repeated measurements to compare
development of tumor size within the groups over time. Until
seven days after treatment comparison of three groups and until 23
days comparison of both verum groups was analysed.
cH2AX phosphorylation in tissue sections. Formalin fixed
paraffin embedded AR42J tumors were cut at 5 mm sections and
immunohistochemically analyzed for cH2AX levels.
A standard immunohistochemical technique was performed
using the rabbit monoclonal antibody to phospho-histone cH2AX
(1:400). Therefore, sections were deparaffinized in xylene and
rehydrated via graded ethanol and PBS. Heat epitope retrieval
was done at 95uC for 60 min in DAKO Target retrieval solution
(DAKO, Hamburg, Germany), followed by annealing at room
temperature for 20 min. Nonspecific binding sites were blocked
with DAKO Protein Blocking Solution (DAKO, Hamburg,
Germany). The primary antibody (1:400; Abcam, Ambridge,
UK) was incubated overnight at 4uC in PBS with 0.2% Triton X-
100. Incubation of the Alexa488-coupled secondary antibody
(1:600; Life Technologies, Darmstadt, Germany) was performed
for 2 h followed by DNA staining with TOPRO-3 dye (1:100; Life
Technologies, Darmstadt, Germany for 30 min at room temper-
ature in the dark. Slides were mounted with Vectashield medium
(Linaris, Dossenheim, Germany) and analyzed by confocal
microscopy with a Zeiss Axio Observer.Z1 microscope equipped
with a LSM710 laser-scanning unit (Zeiss, Oberkochen, Ger-
many). Images were acquired in optical sections of 1 mm and
processed with ImageJ (NIH, USA). Necrotic tissue areas were not
included in the interpretation of immunostaining. The percentage
of cH2AX -positive cells was scored in at least 8 different sections
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of each tumor (,40 cells per section) and data was evaluated by
GraphPad Prism software.
Results
DNA Damage Response in AR42J Cells
First, we characterized the DNA damage response (DDR) of
AR42J pancreatic acinar carcinoma cells following ionizing
radiation. Cells were subjected to gamma irradiation (5 Gy),
which is a well-described inducer of DNA double strand breaks
(DSBs) [17], and incubated for up to 24 h. Western blot analysis
showed a fast and strong phosphorylation of ATM, a phospha-
tidylinositol 3-kinase-related kinase (PIKK) that governs the
cellular stress response to DSBs (Fig. 1A, top panel). This is
consistent with the notion that ATM is activated upon irradiation
by autophosphorylation [18], resulting in the stimulation of ATM-
mediated DSB repair [19]. The IR-dependent activation of ATM
in AR42J cells was accompanied by phosphorylation of its
substrate histone 2AX (cH2AX), which is an established marker
for DSBs [20] (Fig. 1A, bottom panel). As expected, cH2AX
peaked 0.3–1 h upon IR and returned to baseline levels after 24 h,
reflecting the formation and repair of DSBs. In addition, we
analyzed the irradiation-mediated response of p53 and observed
its time-dependent accumulation, starting 1 h after IR (Fig. 1B).
This was followed by induction of its downstream target p21 that is
capable of inducing cell cycle arrest. In contrast, the levels of the
DNA repair protein PARP-1 remained unchanged upon IR.
Taken together, these findings show that AR42J cells activate
the DDR in an ATM-dependent manner following gamma
irradiation and are proficient in p53 signaling as attested by its
accumulation and subsequent induction of p21.
Cell Viability Studies
Viability of pancreatic tumor cells after treatment with 225Ac-
DOTATOC and 177Lu-DOTATOC was measured with the
MTT assay. The colorimetric assay is dependent on the enzymatic
activity of intracellular oxidoreductase that metabolizes the
terazolium dye MTT and reflects the number of viable cells.
Cellular studies showed a reduced viability of AR42J cells after
incubation with 225Ac-DOTATOC at activity concentrations
greater than 2–4 kBq/ml. ED50 values were calculated to
30 kBq/ml after 24 h and 14 kBq/ml after 48 h (Fig. 2). The
same effect was found for 177Lu-DOTATOC, but only at about
700-fold higher activities. 48 h after incubation with 177Lu-
DOTATOC ED50 value was calculated to 10 MBq/ml (Fig. 2).
DNA Damage
DNA double-strand breaks (DSB), localized by cH2AX
staining, increased with higher concentrations of 225Ac-DOTA-
TOC (2.5 to 10 kBq/ml) and 177Lu-DOTATOC (0.6 to 10 MBq/
ml) after 24 and 48 h. The spontaneously detected number of
cH2AX foci in untreated cells was 2 to 5 on average. The data
following incubation with equitoxic doses of 225Ac-DOTATOC
and 177Lu-DOTATOC, extracted from the cell viability data,
showed similar levels of DSB; although with the tendency for the
less complex cH2AX staining to be detectable after treatment with
177Lu-DOTATOC compared to 225Ac-DOTATOC. The average
number of cH2AX foci was 25 at 10 kBq/ml 225Ac-DOTATOC
and 22 at 10 MBq/ml 177Lu-DOTATOC 48 h after incubation.
The maximum number of cH2AX countable was 50. Only in case
of 225Ac-DOTATOC at doses higher than 10–15 kBq/ml pan-
nuclear staining was detectable (Fig. 3). Pan-nuclear staining of
cH2AX was reported previously in IMR90 fibroblasts exposed to
the ß-particle emitter 32P [21]. In addition, nuclear-wide cH2AX
staining was observed after local heavy ion-irradiation and
occurred in an ATM-dependent manner, correlating with the
amount of clustered DNA damage induced [22]. This may also
explain the observed pan-nuclear distribution detected in AR42J
cells after treatment with high dose 225Ac-DOTATOC. Plotting
the average number of cH2AX foci per cell over cell viability after
225Ac-DOTATOC and 177Lu-DOTATOC incubation, respec-
tively, two linear curves were obtained. At the same viability level,
a higher number of DSB per cell were found after incubation with
225Ac-DOTATOC (Fig.4). This might have an effect on cell death
or survival at later time points, due to the powerful induction of
apoptosis after severe DNA damage. However, it demonstrates
that the DSB from alpha particles are of similar down-stream
potency compared to DSB generated from a correspondingly
higher dose of beta-particles.
Figure 1. DNA damage response in AR42J cells following ionizing irradiation. (A) and (B) Cells were irradiated with 5 Gy and time-
dependent DNA damage response was assessed over 24 h using western blot analysis.
doi:10.1371/journal.pone.0088239.g001
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Figure 2. Viability of AR42J cells at 48 h after incubation with 225Ac-DOTATOC (A) and 177Lu-DOTATOC (B).
doi:10.1371/journal.pone.0088239.g002
Figure 3. Number of cH2AX foci in AR42J cells at 24 and 48 h after incubation with 225Ac-DOTATOC (left) and 177Lu-DOTATOC
(right). (A) shows representative images from all activity levels, (B) shows quantification of cH2AX foci and (C) shows two representative examples
for pan nuclear staining after high dose 225Ac-DOTATOC treatment.
doi:10.1371/journal.pone.0088239.g003
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The alkaline comet assay, reflecting DNA single-strand breaks
and DSB and alkali-labile sites in the DNA, showed similar results:
higher doses of 225Ac-DOTATOC resulted in an increased level of
DNA damage (Fig. 5). At equitoxic doses calculated from the
results of the MTT viability assay, 177Lu-DOTATOC showed the
tendency for less tail moment values compared to 225Ac-
DOTATOC. Generally, the variation of the tail moments were
higher in the alpha treated samples, possibly reflecting the fact that
radiation exposure is less homogenous due to the physical
properties of alpha particles. A relative high background tail
moment for Lu-177 irradiated cells might be explained by cross
irradiation over different wells.
Cell Cycle Analysis and Induction of Apoptosis
Cell cycle studies showed an increase in the percentage of tumor
cells in G2/M phase up to 60% already at 24 h (data not shown)
and after 48 h of incubation with 2.5, 5, and 10 kBq/ml 225Ac-
DOTATOC. Further, an increasing amount of polyploid cells
could be detected after 48 h incubation with 225Ac-DOTATOC.
Even at low concentrations of 225Ac-DOTATOC (2.5 MBq/ml),
the amount of cells in G1 phase was decreased (Fig. 6). At a higher
dose the G2/M cell cycle blockage was also detectable (decrease of
S-Phase fraction). After 48 and 72 h of incubation with both
radioconjugates, apoptosis as determined by subG1 flow cytometry
was detectable (Fig. 5).
Biodistribution of 225Ac-DOTATOC and 177Lu-DOTATOC
Biodistribution studies 48 h after injection of tumor bearing
nude mice showed nearly the same binding/uptake of 225Ac-
DOTATOC and 177Lu-DOTATOC in the AR42J tumor of 7.5%
ID/g. Less uptake of both compounds was found in the kidneys
(5.8% ID/g for 225Ac-DOTATOC and 1.5% ID/g for 177Lu-
DOTATOC). In general, higher uptake values were found in all
organs for 225Ac-DOTATOC compared to 177Lu-DOTATOC.
Unexpectedly, high liver uptake (.10% ID/g) was observed for
225Ac-DOTATOC. For this particular case, increased liver uptake
is likely due to approximately 10% free 225Ac that was contained
in the radiolabeled product, compared to only 0.05% ID/g
detectable for 177Lu-DOTATOC. Other measured organs, i.e.
heart and muscle, showed no or only marginal uptake (,1% ID/g)
of 225Ac-DOTATOC and 177Lu-DOTATOC 48 h after injection
of the radionuclides (data not shown).
Generation of DSB and Growth Kinetics of
Neuroendocrine Xenograft Tumors after Treatment with
225Ac-DOTATOC and 177Lu-DOTATOC
The number of cells with at least one clear cH2AX focus was
significantly elevated in tissue sections 48 h after treatment for
both 225Ac-DOTATOC and 177Lu-DOTATOC compared to
nonradioactive controls, whereas overall 225Ac-DOTATOC
treated tumors showed a higher fraction of cells with cH2AX
foci (Fig. 7 A and B). A non-significant increase was also noted for
unlabeled DOTATOC compared to the non-treated control (Fig. 7
A and B). Following a single treatment of tumor-bearing mice with
equitoxic doses of 225Ac-DOTATOC and 177Lu-DOTATOC, we
observed a strong growth delay of 20 and 15 days, respectively,
compared to the corresponding controls (Fig. 7C). Comparison of
tumor growth with a linear statistical model showed differences of
the three groups within the first 7 days after treatment (p = 0.006).
Afterwards, comparing the time curves for the 225Ac-DOTATOC
and 177Lu-DOTATOC groups, this model did not reach statistical
significance (p= 0.174). During the observation period no weight
loss or clinically evident toxicity was noted. This indicates that the
radionuclides at dose levels of approx. 40 kBq 225Ac-DOTATOC
and approx. 30 MBq 177Lu-DOTATOC exert tumor growth
inhibiting effects without significant systemic short-term toxicity.
Discussion
Internal radiotherapy with particle-emitting isotopes coupled to
somatostatin analogues such as DOTATOC has become a widely
accepted therapeutic option for neuroendocrine tumors. Radiola-
belled DOTATOC is rapidly distributed throughout the body and
excreted renally. Rapid binding and uptake into tumor tissue and
long retention are the main reasons for their high therapeutic
effectiveness. These pharmacokinetic properties are ideal for
longer lived isotopes where decay of unbound radioactivity mainly
occurs after excretion. However, cure is seldom achieved and
aspects of dose limiting activities and the potential benefit of other
isotopes are not exactly known. We have hypothesized that at least
in a subset of patients with radio-resistant tumors the use of alpha
emitters might be a further therapeutic option [9]. With its higher
LET, alpha-particles are likely to overcome treatment resistance,
although the biological response to radiation of neuroendocrine
tumors might be generally heterogeneous due to clonal differences
in death pathways and DNA damage repair capacity.
Direct detection of DNA damage is one of the most important
biological markers in assessment of pharmacodynamic effects of
tumor treatments. DSB may be detected on a molecular level by
staining of the early DNA damage response marker, phosphory-
lated histone 2AX (cH2AX). Of note, cH2AX has been shown to
be more sensitive as a marker of DSB than the Comet assay, and
has been recommended as a surrogate clinical marker of DNA
damage [23]. It is also useful to follow up DNA repair since
persisting, non-repaired DSB can be visualised by persisting
cH2AX foci [24].
By comparing the therapeutic isotopes 225Ac and 177Lu, effects
due to differences in dose rates that typically strongly influence
radiobiological responses are minimized. For example, the
temporal cellular responses to radiation from these isotopes are
more comparable than to comparisons between the short-lived
alpha emitter 213Bi (half-life: 46 min) and longer-lived beta
isotopes [25,26]. Furthermore, we accounted for the expected
significant differences in cytotoxicity in the model system using the
Figure 4. Comparison of cell viability and the number of cH2AX
foci in AR42J cells at 48 h after incubation with 225Ac-
DOTATOC and 177Lu-DOTATOC.
doi:10.1371/journal.pone.0088239.g004
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Figure 5. Single-cell gel electrophoresis (alkaline comet assay) of AR42J cells at 24 h and 48 h after incubation with 225Ac-
DOTATOC (A) and 177Lu-DOTATOC (B). DNA damage was calculated by the tail moment, the most frequent used parameter of comet features.
SubG1 fraction of AR42J cells at 48 and 72 h after incubation with
225Ac-DOTATOC (C) and 177Lu-DOTATOC (D).
doi:10.1371/journal.pone.0088239.g005
Figure 6. Cell-cycle distribution of AR42J cells at 48 h after incubation with 225Ac-DOTATOC (left) and 177Lu-DOTATOC (right) (SD
,15%).
doi:10.1371/journal.pone.0088239.g006
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SSR positive cell line AR42J. A comparison between these
isotopes was therefore conducted on equitoxic dose levels of the
alpha- and beta-emitter.
Comparative cytotoxicity assessment demonstrated that a factor
of approximately 700 applies between 177Lu and 225Ac. On this
basis and taking into account the different physical properties, a
relative biological effectiveness of approximately 5 is calculated
(Fig. 2, Table 1), thereby accurately predicting downstream killing
effects. In fact, DNA damage as measured by counting cH2AX-
foci is similarly related to equitoxic doses of both radioisotopes.
Differences between 225Ac-DOTATOC and 177Lu-DOTATOC
as to DSB mediated apoptosis and cell death were relatively low.
Nevertheless, a fraction of cells are more heavily damaged at high
activities of the alpha emitter, as demonstrated by greater tail
moment in the comet assay (Fig. 5), the higher fraction of
polyploid cells on cell cycle analysis (Fig. 6) and in vivo in a slightly
higher tumor control rate (Fig. 7).
cH2AX seems to be an important predictor for radiation-
induced effects, independent of the radiation quality. For example,
a linear relationship between the number of cH2AX-foci and cell
viability for both isotopes is evident (Fig. 4). Furthermore, cH2AX
phosphorylation in the tumor tissue correlated well with the
inhibition of tumor growth (Fig. 7). In line with the in vitro
experiments unexpected significant differences were not detected
between the Ac-225-DOTATOC and the Lu-177-DOTATOC
treated groups. However, the efficacy for both treatments over
controls was demonstrated. Although reliable subcutaneous
growth with small variance is an inherent property of the used
animal model and repeated measurement analysis further reduce
variance, small differences between both radioactive isotopes
cannot be excluded and remain likely. With an in vivo tumor
doubling time of approximately 2 days, a growth delay of 15 to 20
days equals a tumor control fraction of 90–95% of tumor cells
achieved by single treatment with either 44 kBq 225Ac-DOTA-
TOC or 34 MBq 177Lu-DOTATOC. We can speculate, that
differences in DNA repair and apoptosis pathways in some tumor
tissues possibly increase the therapeutic effect of alpha emitters
over beta emitters (for example in hypoxic/radioresistant cells). In
vivo dosimetry cannot be calculated reliably since time activity
information on the tumors was not obtained. On assumption that
half of the number of decays measured at the single time point
(48h after treatment) add to the tumor dose, a rough dose
estimation could be made from a tumor tissue activity concentra-
tion of 45 kBq * 0.075 ID/g=3.4 kBq/g for 225Ac-DOTATOC
and 35 000 kBq/g * 0.075 ID/g= 2625 kBq/g for 117Lu-DOTA-
TAOC. These activity concentrations are thus multiplied by 0.5
(some of the tumor bound activity will be released and some will
decay at time points where an effect on tumor is no longer
Figure 7. Immunofluorescence staining of DNA double strand breaks (cH2AX) in AR42J tumors after treatment with 47 kBq 225Ac-
DOTATOC, 30 MBq of 177Lu-DOTATOC, 1 mg DOTATOC (unlabelled), or PBS. (A) Representative images, (B) and quantification of cH2AX-
positive cells. Scale bar (white) corresponds to 25 mm. (C) Growth delay after treatment with equitoxic doses of 225Ac-DOTATOC (n = 3, 44kBq/mouse)
and 177Lu-DOTATOC (n = 4, 34 MBq/mouse) versus untreated control (n = 4).
doi:10.1371/journal.pone.0088239.g007
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expected) and energy is calculated from numbers of decays and
particle energy/decay [27,28]. After conversion of the respective
units (electronvolts to joules with 1.6E-13 J/MeV, and g to kg,)
such an estimate would deliver approximately 10 Gray of alpha
particle dose and 25 Gy of beta particle dose. This moderately
decreases the in vivo RBE of alpha radiation compared to values
measured in vitro. After a single treatment most of the radiation
dose to tumors and organs are delivered within the first few days
depending on the biologic half-life of radiolabeled somatostatin
analogue that add to the physical half-life (resulting in the effective
half-life). Tumor growth after one single treatment was delayed
well above two half-lives of the radioisotopes, reflecting long-term
effects after initial radiation. Integrity of the peptide and its link to
the radioisotope is ensured over several days, but upon decay the
daughter nuclides from 225Ac are released and distributed with
their own pharmacokinetics [29]. Nevertheless, due to rapid initial
distribution and diffusion into tissue of the peptide together with
high affinity binding to their receptors and high internalization
into tumor cells delivery of radiation is determined significantly by
the early component of the biodistribution.
Compared to other cell lines from which data are available,
AR42J cells do not display great sensitivity towards 225Ac. Activity
concentrations of up to 2 orders of magnitude higher than in other
studied systems are required to devitalize 50% of cells [6,29].
However, an exact comparison is not possible due to different
assays and time points. The AR42J cell line retained the p53
transactivation activity and apoptosis execution and represents,
therefore, a reasonable model for our studies [30]. This was
further corroborated by our initial experiments showing an IR-
dependent induction of the DDR in AR42J cells with activation of
p53 and repair of DSBs as reflected by cH2AX kinetics (Fig. 1).
Alpha resistance in leukemia cells has been induced at low doses
and was attributed to several factors including reduced apoptosis,
G2 checkpoint maintenance and increased DNA repair [31]. Cell
cycle analysis after 225Ac-DOTATOC or 177Lu-DOTATOC
treatment points to a similar direction with a higher fraction of
G2/M cells for alpha irradiation at low doses compared to beta
irradiation (Fig. 6).
In contrast to external beam radiation, internal radiotherapy
displays several differences that influence its mechanism of action.
In addition to generally more inhomogeneous spatial dose
distribution for example within tumor tissue, temporal dose
distribution is neither discrete nor is it fractionated. It is a
continuous radiation with exponential decline according to the
half-live of the therapeutic radioisotope. Thus, radiation response
including adaptive responses like repair and cell cycle arrest might
be different. For optimal application of internal radiotherapy
applied activities and its fractionation into different cycles cannot
be easily concluded from experience with external radiation. To
establish the most beneficial application regimens and possible
combination of different isotopes and combination of internal and
external radiation cH2AX quantification might play a key role.
Pan nuclear staining might be a general stress response due to
radiation that differs from localized response to a limited number
of DNA-damage [21]. It will complicate quantification of cH2AX
foci at higher concentrations. However, its investigation might add
information to the spatial dose distribution of higher doses, which
might be important for the more inhomogeneous dose distribution
of alpha radiation.
For further development of internal carrier-driven radiotherapy,
a profound understanding of the underlying mechanism is
essential. Especially, with increasingly successful use of the
relatively long-lived beta emitter 177Lu, the additional potential
of other therapeutic isotopes such as the long-lived generator
nuclide 225Ac needs to be characterized. Our model system
displayed similarities between the two radiation types at
therapeutic active doses with a tendency of delayed DNA damage
for the alpha emitter. In this model we have shown high tumor
control rate in vivo after single treatment with both isotopes
mediated by somatostatin receptor targeting. Interestingly, molec-
ular effects like apoptosis and in vivo effects like tumor growth were
accurately correlated to the number of DSB detected by cH2AX.
Therefore, we conclude this marker can serve as an early key
surrogate marker for therapeutic effects following internal
radiotherapy.
Table 1. Physical properties of the radio-isotopes and calculation of their relative biological effectiveness on basis of 48 h in vitro
cytotoxicity.
Comparison of physical properties
Isotope alpha particle energy (MeV) beta particle energy (MeV) total particle energy/decay
Ac-225 5.8
6.3
7.1
8.3 0.66
28.16
Lu-177 0.147
0.147
Ratio after total decay: 192
Ratio after 48 decay: 131
Comparison of cytotoxicity ED 50% (kBq/ml)
Lutetium-177-DOTATOC 10000
Ac-225-DOTATOC 14
Ratio of cytotoxicity: 714
Relative Biological Effectivness (after 48 h): 5
doi:10.1371/journal.pone.0088239.t001
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